Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Phase 3 clinical trial results released in May 2026 showed participants lost up to 28.3% of their body weight over 80 weeks, making it potentially more effective than semaglutide (Ozempic and Wegovy) and tirzepatide (Zepbound and Mounjaro)
mean 20.440.5 vs 5.69.3 h
doi:10.1002/adtp.202400028
They included 12 SGLT2i trials with 73,238 participants, of whom 3,065 were on a GLP-1 RA: they found that the benefits of SGLT2i on MACE were consistent regardless of background GLP-1 RA use (HR = 0.81 in patients receiving GLP-1 RA vs HR = 0.90 in those not receiving GLP-1RA) with no significant heterogeneity (p = 0.31)
Even so, detection still depends heavily on the type of test being used
